Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

News Release

Tonix Pharmaceuticals' CEO reveals next-generation COVID vaccine technology chosen for key program

Tonix Pharmaceuticals

Tonix Pharmaceuticals CEO Dr Seth Lederman recently joined Steve Darling from Proactive to share exciting news about their COVID vaccine, TNX-1800, selected for testing in Project Next Gen, a White House initiative managed by the Department of Health and Human Services, NIH, and NIAID. The vaccine is based on a live virus platform, providing a unique approach to waking up the immune system. Live virus vaccines, like TNX-1800, offer more durable immunity that lasts a long time and can potentially block virus transmission, addressing limitations seen in mRNA vaccines. This choice of TNX-1800 is a testament to Tonix's nearly decade-long dedication to vaccine development. The technology platform can also be adapted to protect against other infectious diseases, such as monkeypox, smallpox, and tuberculosis, making it a versatile solution for future pandemics. This development highlights the significance of vaccine platforms for tackling various infectious threats. Tonix's approach promises to offer more robust, long-lasting immunity and potential transmission prevention, which could revolutionize our approach to infectious disease control. The platform's adaptability positions it as a valuable tool for future vaccine strategies. Contact Details Proactive Studio +1 347-449-0879 na-editorial@proactiveinvestors.com

November 20, 2023 01:57 PM Eastern Standard Time

Video

News Release

Tonix Pharmaceuticals finish Phase 3 trial of TNX-102 SL for management of Fibromyalgia

Tonix Pharmaceuticals

Tonix Pharmaceuticals CEO Dr Seth Lederman recently joined Steve Darling from Proactive to shed light on the latest developments in their research efforts. The company has successfully concluded the clinical phase of a Phase 3 registration-quality study for TNX-102 SL, a drug developed for the management of fibromyalgia. This study, which is double-blind and placebo-controlled, saw the enrollment of 457 patients across various sites in the United States. Lederman conveyed to Proactive that the topline results from this study are anticipated by late December. Should the results be favorable, this trial is expected to be the conclusive well-controlled efficacy trial needed for the submission of a New Drug Application to the U.S. Food and Drug Administration. The urgency and importance of this development are underscored by the fact that an estimated 6-12 million individuals in the US are afflicted with fibromyalgia, a condition that predominantly affects women. In addition to the TNX-102 study, Lederman also discussed another significant milestone: the enrollment of the first participant in a Phase 2 study, supported by the Department of Defense, focusing on TNX-1900 for the improvement of bone health in children with autism spectrum disorder. This investigator-initiated trial represents a foray into addressing the complex needs of children with autism, potentially offering a new therapeutic avenue to enhance their quality of life. Contact Details Proactive Studio +1 347-449-0879 na-editorial@proactiveinvestors.com

November 20, 2023 01:53 PM Eastern Standard Time

Video

Oxford Cannabinoid Technologies strengthens board with CMO Dr. Tim Corn

Oxford Cannabinoid Technologies Holdings PLC

Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTC:OCTHF) CEO Clarissa Sowemimo Coker and CMO Dr Tim Corn speak to Thomas Warner from Proactive after the pharmaceutical group announced the appoint of Corn to its board of directors. The move follows his appointment as Chief Medical Officer in June 2023. Sowemimo-Coker highlights the importance of having a clinician on the board of a biopharmaceutical company. The appointment follows the successful announcement of Phase I single ascending dose results in October, reflecting OCT's commitment to addressing unmet medical needs with novel therapeutic approaches. Dr. Corn cites the combination of addressing unmet medical needs and the use of a novel cannabinoid approach as key factors that have attracted him to the business. He outlines his dual focus in the role, continuing as CMO to ensure efficient clinical programs aligned with regulatory requirements and bringing a physician's perspective to the board. He suggests that his expertise in clinical development and board work positions him well to balance patient interests and financial considerations. Discussing the company's cash runway, Sowemimo-Coker says the company is funded into April 2024. She assures stakeholders that the board is actively exploring various funding options, and updates will be provided as progress unfolds. While the details remain confidential, she hints at potential updates before the end of the year. The interview showcased OCT's commitment to advancing cannabinoid-based therapies, building a strong leadership team, and maintaining transparency in financial matters. Stakeholders are eagerly anticipating further developments as OCT continues its journey towards clinical and financial success. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

November 20, 2023 10:24 AM Eastern Standard Time

Video

AGC Biologics to Prepare Late Phase and Commercial Runs for Immunocore

AGC Biologics

AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new late-stage clinical and process performance qualification (PPQ) project at its Heidelberg, Germany site with Immunocore Holdings Plc (Nasdaq: IMCR). Immunocore intends to use the Heidelberg site to complete late-stage manufacturing and prepare for commercialization for IMC-F106C, Immunocore’s PRAME-targeted bispecific therapy. Under the agreement, AGC Biologics will leverage its microbial fermentation and manufacturing experience to perform bench-scale qualification and process characterization, and other required studies to support phase III manufacturing, as well as PPQ runs. Pending a successful PPQ campaign and regulatory approvals, the Immunocore project is expected to move into commercial stages at the AGC Biologics Heidelberg site. This is the next step in the partnership for this candidate between the two companies, with AGC Biologics providing early-phase support for this same project. Immunocore and AGC Biologics previously worked together on commercial manufacturing readiness for KIMMTRAK® (tebentafusp-tebn) at the CDMO’s Copenhagen site. “This is a great example of the power of the AGC Biologics network and our ability to collaborate at our global sites to support important client projects,” said Dieter Kramer, General Manager, AGC Biologics Heidelberg. “I am extremely proud of our team here in Heidelberg and the work they’ve done to support this project. We are pleased Immunocore has agreed to work with us on these next important steps in their product’s lifecycle, as our team has the late-stage and commercial expertise to deliver what is needed.” AGC Biologics runs multiple cGMP microbial fermentation lines at its Heidelberg facility. The AGC Biologics Heidelberg site has produced biologics products for 40 years and has built a track record for navigating clients through the early clinical phases and into later stages to help prepare for commercial production. In addition to fermentation, the site serves as a center of excellence for plasmid DNA (pDNA) and messenger RNA (mRNA). To learn more about AGC Biologics’ microbial system-based biologics, plasmid DNA (pDNA) and messenger RNA (mRNA) manufacturing site in Heidelberg, visit www.agcbio.com/facilities/heidelberg. For more information on the company’s Protein Biologics, pDNA, Cell Therapy, Viral Vector and mRNA drug product services go to www.agcbio.com. About AGC Biologics AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, every step of the way. We provide world-class development and manufacture of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with cGMP-compliant facilities in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba, Japan and we currently employ more than 2,500 employees worldwide. Our commitment to continuous innovation fosters the technical creativity to solve our clients’ most complex challenges, including specialization in fast-track projects and rare diseases. AGC Biologics is the partner of choice. To learn more, visit www.agcbio.com. Contact Details AGC Biologics Nick McDonald +1 425-419-3555 nmcdonald@agcbio.com

November 20, 2023 05:08 AM Eastern Standard Time

News Release

Breaking ground in vision restoration: Kiora Pharmaceuticals reveals promising results with KIO-301

Kiora Pharmaceuticals

Kiora Pharmaceuticals CEO Brian Strem joined Steve Darling from Proactive to share news the company's plan to broaden the clinical development of KIO-301, a treatment designed for various inherited retinal diseases. The expansion includes initiating a Phase 2 trial which will be controlled, double-masked, randomized, and will involve an ascending dose. This trial is set to include up to 20 patients suffering from Retinitis Pigmentosa (RP), who will receive doses monthly over a span of 90 days. Strem explained that this move is propelled by encouraging topline results from a Phase I/II clinical trial, which indicated that KIO-301 is a first-in-class small molecule with significant potential to improve vision for patients with RP, even those with extremely low vision or complete blindness. Moreover, Kiora Pharmaceuticals has plans to engage with the FDA in the fourth quarter of 2023. The goal of this meeting is to achieve consensus regarding the study designs, endpoints, and additional requirements necessary to conduct further studies in the United States and Europe. These studies would not only target RP but also extend to other inherited retinal diseases such as Choroideremia (CHM) and Stargardt disease. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

November 17, 2023 01:54 PM Eastern Standard Time

Video

Arecor Therapeutics takes major step with first commercial sale of AT220

Arecor Therapeutics PLC

Arecor Therapeutics PLC CEO Sarah Howell speaks to Thomas Warner from Proactive after the biopharmaceutical group announced the first commercial sale of a product that incorporates its proprietary Arestat technology, known as AT220. Part of a licence agreement with an unnamed global pharma partner initiated in 2017, the milestone has triggered a payment to Arecor. It will also receive royalties on sales. Howell explains the significance of the news, emphasising its importance for patients and the business. She says the achievement aligns with Arecor's vision of building a large, self-sustaining biopharmaceutical company focused on improving patient care. While the partner involved in this achievement remains undisclosed, Howell shed light on Arecor's appeal to pharmaceutical collaborators and says the Arestat technology enables the company to enhance biosimilar products, providing more benefits to patients and giving partners a competitive edge in a high-value market. She says the financial impact is significant, with the milestone triggering licensed payments and initiating recurring royalty streams for Arecor. As the year approaches its end, Howell hints at potential updates. The partnered portfolio shows promising progress, with recent announcements of licensed milestones and positive developments in clinical studies. Ongoing partnerships with pharmaceutical and biotech companies are expected to expand, contributing to Arecor's growth. The company is actively developing its proprietary products, focusing on specialty hospital medications and diabetes treatments. One of their lead diabetes products, AT278, targets patients with high insulin needs, presenting a disruptive solution in a growing market segment. Results from the clinical study are anticipated in Q1 2024. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

November 17, 2023 12:47 PM Eastern Standard Time

Video

News Release

NRx Pharmaceuticals founder unveils potential treatment for suicidal thoughts and depression

NRx Pharmaceuticals Inc

NRx Pharmaceuticals founder and chief scientist Dr Jonathan Javitt joined Steve Darling from Proactive to discuss groundbreaking developments in treating suicidal ideation and depression. NRx focuses on targeting the NMDA (N-methyl-D-aspartate) receptor in the brain, identified as crucial for turning off suicidal thoughts. Traditional antidepressants, which target the serotonin axis, often increase suicide risk, highlighting the need for a new approach. Javitt told Proactive the company is approaching the clinical trial enrollment goals for its partnered product NRX-101, while opening new clinical initiatives in chronic pain, urinary tract infection, and NRX-100 for suicidal depression. The company said the trial is near completion of enrollment of the originally-targeted 70 participants in the Phase 2b/3 trial of NRX-101. Top-line data from this cohort of patients is expected shortly after the last patient visit. Javitt told Proactive chronic pain affects more than 50 million American adults, compared to the approximately 3 million who report thoughts of suicide on an annual basis. There has been no new non-opioid class of drugs to treat nociceptive pain in the past two decades and NRX-101 has the potential to be the first NMDA-antagonist drug to seek approval for this indication. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

November 16, 2023 02:07 PM Eastern Standard Time

Video

Navigating Open Enrollment

YourUpdateTV

Open Enrollment season is underway, and as we look ahead to 2024, now is the time to assess health care coverage options and select the plan that is best for you and your budget. Recently, Rhonda Randall, the Chief Medical Officer of UnitedHealthcare Employer and Individual participated in a nationwide satellite media tour to share tips for navigating the Open Enrollment season. A video accompanying this announcement is available at: https://youtu.be/mhpkMs2vBGk Enrollment periods aren’t the same for everyone, so there are key dates to keep in mind depending on your circumstances. Many employers set aside a 2- to 3-week period between September and December when employees can select health benefits for the following year. But just as millions of Americans prepare to choose health insurance for next year, a recent survey revealed that 1 in 3 people (36%) spend less than 1 hour reviewing their benefits options. For most people, not making an enrollment decision means you may be locked into your current plan for the upcoming year. If anything has changed this year – either with your current plan, health status or budget – that decision to do nothing could lead to unpleasant surprises or missed cost-savings in 2024. Because everyone has unique health and budget needs, and there is no one-size-fits-all approach to selecting a health plan, it’s important to stay informed before making these decisions. When choosing a health plan, here are a handful of tips that will hopefully lead to better health and cost savings: Take your time and consider all of your options Learn the language Help prevent financial surprises Check for mental health coverage Don’t forget about specialty benefits Look into wellness programs Explore virtual care services Visit UHCOpenEnrollment.com for tips, resources and information on plans in your area About Rhonda Randall Rhonda L. Randall, D.O., is the Chief Medical Officer of UnitedHealthcare Employer & Individual, the nation’s largest business serving the health coverage and well-being needs of nearly 28 million Americans. Dr. Randall collaborates with U.S. employers who are looking for quality, cost-effective, long-term solutions to health benefits for their employees and retirees. She also leads the clinical strategy development for these businesses to improve quality outcomes, ensure affordability and improve health and well-being. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

November 16, 2023 11:00 AM Eastern Standard Time

Video

PathAI Announces AISight Support of DICOM Standards and Commits to Being a Leader in Integrated Enterprise Image Architecture and Strategy

PathAI

PathAI, a leading technology company which combines AI-powered pathology solutions with end-to-end central pathology and histology services, today announced that AISight™ [1] supports rendering DICOM® Visible Light (VL) Whole Slide Microscopy Image files. AISight is a state-of-the-art, interoperable, intelligent case and image management system to assist pathologists in the review of digitized whole slide images (WSIs) with a comprehensive menu of fully embedded AI solutions. The incorporation of modern digital pathology into the DICOM standard was finalized in 2010, allowing organizations to integrate digital pathology into their existing IT systems, providing vendor flexibility, and enabling integrated storage with other imaging modalities (e.g., radiology) in vendor neutral archives (VNAs). DICOM support is a major advancement towards enabling PathAI’s vision of interoperable pathology systems that fit seamlessly into providers current or future enterprise image architecture and strategy. “We’ve been collaborating with many large academic medical centers and health systems over the last year to provide consultative support on digitalization of pathology workflows. In these discussions, one thing is clear. Chief information officers (CIOs) and enterprise imaging architects are pushing for vendors to adopt DICOM to drive imaging interoperability,” said Don O’Neill, SVP of Engineering and IT at PathAI. “PathAI is committed to doing just that and being able to render DICOM image files is the first step in that direction.” As part of its investment into DICOM, PathAI is making a commitment to interoperability and providing solutions that integrate with organizations’ enterprise image management and archive strategy, including through VNAs. PathAI will also launch its DICOMweb API in its next release, which will enable AISight to receive DICOM images from external applications, push images back to VNAs leveraging customer’s DICOMweb API, utilize the DICOM file to supplement or validate image/case data, and enable prefetch to pull historical cases/studies directly from image archives. “By investing into interoperability with enterprise image archives, we’re demonstrating to our customers that we are strategically positioned to provide long term value. No matter where a customer is in the imaging journey, we can help them,” said Andy Beck, MD, PhD, co-founder and chief executive officer of PathAI. To learn more about this integration, visit www.PathAI.com or meet with our team at upcoming conferences including Digital Pathology & AI Congress Europe, London (Booth #30, December 7-8). 1- AISight is for Research Use Only. Not for use in diagnostic procedures. About PathAI PathAI is the only AI-focused technology company to provide comprehensive precision pathology solutions from wet lab services to algorithm deployment for clinical trials and diagnostic use. Rigorously trained and validated with data from more than 15 million annotations, its AI-powered models can be leveraged to optimize the analysis of tissue samples to improve efficiency and accuracy of pathology interpretation, as well as to better gauge therapeutic efficacy and accelerate drug development for complex diseases. PathAI, which is headquartered in Boston, MA, and operates a CAP/CLIA-certified laboratory in Memphis, TN, is proud to be a rapidly expanding organization of innovative thinkers from around the globe. For more information, please visit www.pathai.com. Contact Details SVM Public Relations and Marketing Communications Maggie Naples +1 401-490-9700 pathai@svmpr.com Company Website https://www.pathai.com/

November 16, 2023 10:00 AM Eastern Standard Time

1 ... 50 51 52 53 54 ... 210